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 4 
Abstract 5 
Health care professionals who prescribe medicines have the professional duty to choose medicines that 6 
are in the best interest of their individual patient, irrespective if that patient is an adult or a child. 7 
However, the availability of medicines with an appropriate label for paediatric use is lagging behind those 8 
for adults, and even available paediatric drugs are sometimes not suitable to administer to children. 9 
Consequently, health care professionals often have no other option than to prescribe off-label medicines 10 
to children. An important reason for use of off-label medicines is to improve access to (innovative) 11 
treatments or to address medical needs and preferences of patients, especially when no other options 12 
are available. However, off-label use of medicines is in general not supported by the same level of 13 
evidence as medicines licensed for paediatric use. This may result in increased uncertainty on efficacy as 14 
well as the risk for toxicity and other side effects. In addition, liability may also be of concern, 15 
counterbalanced by professional guidelines.  16 
Conclusion: The purpose of this joint EAP/ESDPPP policy statement is to offer guidance for physicians on 17 
when and how to prescribe off-label medicines to children and to provide recommendations for future 18 
European policy. 19 
 20 
List of abbreviations 21 
BNF-c: British National Formulary for Children 22 
CJEU: Court of Justice of the European Union 23 
EAP: European Academy of Paediatrics 24 
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GP: general practioner 26 
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PICU: paediatric intensive care unit 28 
PTLD: post-transplant lymphoproliferative disease 29 
NICU: neonatal intensive care unit 30 
NKFK: Dutch Expertise Centre for Pharmacotherapy in Children  31 
RTU: recommendations for use 32 
SmPC: summary of product characteristics 33 
 34 
Introduction  35 
Health care professionals (HCPs), in close collaboration with pharmacists, who prescribe medicines, have 36 
the professional duty to choose medicines that are in the best interest of their individual patient. 37 
However, the availability of medicines with an appropriate label for paediatric use is lagging behind those 38 
for adults and available paediatric drugs are often not suitable to administer to children [1]. As a result, 39 
physicians often have no other option than to prescribe medicines to children outside the approved 40 
conditions for age, therapeutic indication, dose recommendation, formulation and/or route of 41 
administration (i.e., off-label use [2]) or to prescribe a drug which has not received a license for use in 42 
adults or children (i.e., unlicensed medicines use [2]). The practice of off-label prescribing of medicines to 43 
children is substantial, both in hospital care and primary health care [3]. A recent report on the setting in 44 
the European Union indicates that off-label use of medicines in children is still widespread. Off-label use 45 
varies among European countries, with 13-69% of prescriptions being off-label in the hospital setting and 46 
2-100% in primary care [4].   47 
European guidelines on off-label use of medicines in children could greatly benefit children, parents and 48 
their HCPs.  Therefore, the purpose of this policy statement is to offer guidance for these HCPs, and to 49 
provide recommendations for any future European policy. 50 
 51 
European views on off-label use of medicines 52 
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According to recent survey findings among European stakeholders, off-label use of medicines is perceived 53 
to have both advantages and disadvantages. An important advantage is the accelerated access of 54 
patients to (innovative) treatments and the appropriate treatment of medical conditions in patients, 55 
when no other options are suitable [4].  56 
The development of medicines for children is complicated by a small and heterogeneous market, and 57 
methodological and ethical requirements for paediatric trials [5].  As a result, many medicines are not 58 
labelled for use in children. It has been estimated that more than 50% of medicines used in children have 59 
not been tested for the specific age group [6]. In addition, medicines labelled for use in children may 60 
underperform with respect to their ability to provide the recommended dose, the suitability of the 61 
dosage form and the presence of potential harmful excipients [7]. For example, the availability of melting 62 
or chewable tablets, more likely taken by younger children, appears to be limited [1]. Typical therapeutic 63 
areas of off-label use in children include – but are not limited to - infectious diseases, cardiology, 64 
dermatology, pain treatment, alimentary tract and metabolism, the respiratory system and the central 65 
nervous system [4]. The highest frequency of off-label use of medicines is seen in patients treated in the 66 
NICU, PICU and children with oncologic diseases.  67 
By using off-label medicines, prescribers, children and their families have more treatment options to 68 
discuss in order to provide a treatment that one finds most appropriate for the needs of the individual 69 
patient. In addition, based on the newest available scientific evidence, (innovative) medicines (type of 70 
drug, dose and/or indication) can be prescribed to patients at an earlier stage before the required 71 
regulatory approval has been finalized, or adapted [4]. However, as off-label use of medicines are in 72 
general not supported by the same level of pre-clinical and clinical evidence as medicines licensed for 73 
paediatric use, this may result in increased uncertainty on efficacy as well as the risk for toxicity [7] and 74 
prescribers and patients have less information at their disposal to decide to choose (prescriber) or accept 75 
(patient) the off-label treatment [4]. Finally, the issue of liability may also be a concern, counterbalanced 76 




Off-label prescribing is not regulated by European law [9]. European legislation only regulates the 79 
marketing of medicines and not the way medicines are ultimately used in clinical practice, which is a 80 
national competence, or is captured in ‘para’legal statements or guidelines on good practice. Prescribing 81 
on-label or off-label medicines is a decision taken within the relationship between a patient and the 82 
prescriber. The professional setting (both legal, and ‘para’legal) does not limit the right of prescribers to 83 
prescribe medicines to “on-label” prescriptions only, as this would in many cases lead to a conflict of 84 
professional duties. Therefore, in practice, at the national level off-label use of medicines is often 85 
ethically and legally ‘accepted’ under restrictions.  86 
Several European countries have adopted special statutory regulations for off-label use of medicines, and 87 
have good practice or professional guidelines for use, including reimbursement decisions (Tables 1-3). 88 
These regulations or policy tools aim for improvement of knowledge regarding efficacy and safety of off-89 
label use. This regulation to encourage pharmaceuticals to file a license extension and/or to create the 90 
opportunity to apply research results immediately in a licensed setting, are counterbalanced by the 91 
uncertainties related to reimbursement practices. In countries where no policy tools are in place, the 92 
predominant argument is that off-label use of medicines is an issue that should be dealt with in the 93 
context of the relationship between prescriber and patient rather than at level of the regulatory or 94 
healthcare system [4].  95 
 96 
European policy statement on prescribing off-label or unlicensed drugs to 97 
children 98 
Off-label use of medicines is subject to several conditions. According to the Court of Justice of the 99 
European Union (CJEU), off-label use should remain exceptional in order to preserve the practical effect 100 
of the licensing procedure for medicines. Prescribing off-label medicine: (1) should be limited to 101 
individual situations justified by medical considerations; (2) should be under the responsibility of the 102 
prescriber; (3) presupposes that the medicine is necessary to address the needs of the patient; (4) should 103 
follow a full assessment and examination of the patient, and (5) should be decided on the basis of purely 104 
therapeutic considerations [4].  105 
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Physicians who prescribe off-label medicines to children should comply with ethical and professional 106 
standards. Divergence in drug and social laws, institutional, and professional rules across Europe may 107 
complicate a uniform approach to prescribing off-label medicines in children. Nevertheless, the European 108 
Academy of Paediatrics and the European Society for Developmental, Perinatal and Paediatric 109 
Pharmacology strongly recommend that the following conditions are considered when prescribing off-110 
label medicines to neonates, infants, children or adolescents. We hereby suggest that this may serve as a 111 
checklist for defensible, good practice.  112 
 113 
Condition #1: All other options, including the use of medicines approved by the regulatory 114 
authorities, are unavailable, not tolerated, less than optimal, too expensive, not 115 
reimbursable by insurance companies, or containing potentially harmful excipients.  116 
Off-label use is not the same as off-knowledge use. 117 
 118 
Condition #2: The prescriber is competent to prescribe off-label medicines in children. 119 
An off-label medicine can only be prescribed by someone who has prescribing skills (rational drug 120 
therapy) and is knowledgeable about off-label use of medicines in children [10]. Importantly, in this 121 
process there is a major role of the pharmacist who is able to provide or produce the drug 122 
extemporaneously. As children differ from adults with regards to disease aetiology, pharmacokinetic and 123 
pharmacodynamic factors and formulation acceptance, the prescriber should have specific knowledge 124 
and experience in the field of paediatrics. Although most physicians appear to be familiar with the 125 
practice of off-label prescribing, most are not aware that the medicines they prescribe are indeed off-126 
label medicines [11]. As this may have consequences for the monitoring of efficacy and adverse events, it 127 
is crucial that the prescriber should be aware that he or she is prescribing the medicine in an off-label 128 




Condition #3: Off-label prescription of the medicine is appropriate to meet the needs of 131 
the individual patient within the available resources. 132 
There are several situations in which it may be necessary to prescribe a medicine in an off-label manner.  133 
 There may be a medical need where there is no labelled medicine available [4], or the labelled 134 
formulation or dosage is not age-appropriate. For example, most medicines used in neonatology 135 
have not been tested for the appropriate age and weight group and most doses have been 136 
extrapolated from adult and older children. Moreover, the risk of administration errors can be 137 
reduced if age-appropriate off-label drug formulations are prescribed. In addition, off-label use is 138 
the rule and not the exception in patients with rare diseases, like clobazam for epilepsy in Dravet 139 
syndrome.  140 
 Certain medicines may be licensed, available and suitable for use in children in one country, but 141 
not in another; for example midazolam oral suspension that is available in Germany but not in 142 
Belgium. 143 
 The licensed medicine may (no longer) be appropriate (has become obsolete), for example due 144 
to the use of harmful excipients, and an off-label medicine provides an appropriate alternative to 145 
use.  146 
 An off-label medicine may address patient needs better than the licensed medicine in cases 147 
when the licensed medicine is not effective, or causes unacceptable side effects, resulting in 148 
lower treatment adherence [4].  149 
 Off-label use may be part of the professional treatment guideline [4], for example in cases where 150 
product summaries have not been updated (yet) despite available evidence [12], such as 151 
aminoglycoside dosing in neonates and infants. This type of off-label use allows physicians to use 152 
existing medicines in an innovative way, when evidence exists but formal licensing for children 153 
has not taken place (yet) [4], as may be the case in paediatric oncology (e.g., rituximab for 154 
treatment of post-transplant lymphoproliferative disease (PTLD). 155 
 156 
Condition #4: The off-label prescription should be rational and clinically appropriate.  157 
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As with licensed use of medicines, the prescriber must ensure the off-label prescription is appropriate [4]. 158 
All medicines have associated risks of adverse events. In the case of on-label prescribing, the prescriber 159 
can rely on the medicine’s evaluation by the competent authorities. In the case of off-label prescribing, 160 
the prescriber has to weight the benefit-risk ratio. Off-label prescribing is considered appropriate if (1) it 161 
is justified by best available evidence, preferably based on professional guidelines supported by relevant 162 
societies (e.g. national paediatric and/or pharmacist societies); (2) it occurs within the context of a formal 163 
research protocol; or (3) it pertains to exceptional use, justified by individual clinical circumstances. If 164 
none of these justifications is present, its use is generally not recommended [adapted from 13].  165 
If off-label prescribing is considered appropriate, the prescriber will not automatically be liable for 166 
negative impacts on the patient’s health, especially if the off-label use is mentioned in a professional 167 
guideline or formulary.  168 
Rational pharmacotherapy requires that patients receive medicines appropriate to their clinical needs, in 169 
doses that meet their own requirements, for an adequate period of time, and at a reasonable cost to 170 
them and their community [14]. Formularies may be effective in improving rational pharmacotherapy in 171 
children [15]. In the United Kingdom and The Netherlands, physicians prescribing medicines to children 172 
are guided by information in the British National Formulary for Children (BNF-c) and the Dutch National 173 
Formulary for Children. In the Netherlands, the development of this open-access formulary has resulted 174 
in the revision of many consensus-based dose recommendations, and ensured uniformity in prescribing 175 
habits in the Netherlands [16]. However, it is important to emphasize that these formularies have still 176 
knowledge gaps, like for optimal use of medicines in preterm neonates. 177 
 178 
Condition #5: The patient, parents/caregivers should be informed and involved. 179 
When considering prescribing an off-label medicine, both children and their parents/caregivers should 180 
have all the appropriate information available, if possible, regarding that medicine.  181 
There is limited published literature about the views of patients, parents and healthcare professionals 182 
regarding informed consent in off-label or unlicensed use of medicines in children. In general, most 183 
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children [17], parents [11,18], and citizens [19] feel that parents should be informed when a medicine is 184 
prescribed in an off-label or unlicensed manner, for example to create alertness to potential side effects 185 
[17]. In addition, most children feel that also the child (in case of older child) should be informed [17]. 186 
The literature from health care professionals is more mixed: most healthcare professionals in Northern 187 
Ireland [20] felt that parents should be informed, whereas hospital-based paediatricians in Scotland did 188 
not [21]. Knowledge about off-label or unlicensed use of medicines in children is low among the general 189 
public [19] and in different studies of parents of healthy and chronically ill children [11,18]. A minority of 190 
hospital-based paediatricians [21] and of general practitioners [22] (GP) in Scotland informed a child’s GP 191 
[21] or the parents [22]. Once parents knew that their children were prescribed off-label medicines, 192 
parents would ask for a licensed medicine [18,19] or they would use the medicine with more caution 193 
[19]. The percentage of refusal of off-label use was higher among parents of healthy children compared 194 
with parents of chronically ill children [23]. 195 
Several national policy tools indicate patients should be informed and provide consent when prescribing 196 
off-label or unlicensed medicines (Tables 1 and 3). According to the Royal College of Paediatrics and Child 197 
Health, in general, when prescribing off-label medicines to children, it is not necessary to take additional 198 
steps to obtain consent of parents, caregivers and children beyond those taken when prescribing licensed 199 
medicines [24]. This is in line with the policy statement issued by the American Academy of Pediatrics in 200 
2014, which states that administration of off-label medicines in children does not warrant special consent 201 
if it is based on sound medical evidence. However, if the off-label use is experimental, then the patient 202 
(or parent) should be informed of its experimental status [25]. European paediatricians should know and 203 
abide by the appropriate informed consent laws in their respective countries. 204 
 205 
Condition #6: The patient should be monitored for efficacy and adverse events.  206 
As off-label or unlicensed use of medicines may result in altered efficacy and an increased risk for harm 207 
and hospitalization [8], the prescriber and pharmacist should ensure appropriate monitoring. Adverse 208 
events should be reported to the national pharmacovigilance system by HCPs, but also by the families 209 
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(parents and or children). In case where medicines are prescribed that have reasonable rationale for use, 210 
but insufficient evidence to mitigate safety, efficacy and cost-effectiveness concerns, yet they are not 211 
part of clinical research (“innovate off-label use”), then outcomes should be evaluated prospectively, 212 
documented appropriately, and reported to all stakeholders (health care providers and patients) in a 213 
timely fashion. Regular review should occur to reduce the risk of continued use that is not efficacious or 214 
is unsafe [28]. In this way, this condition is true for any prescription, including off label or unlicensed use.  215 
 216 
Condition #7: The prescriber should consider if off-label prescribing should be part of a 217 
clinical trial. 218 
Finally, in order to increase our knowledge about the efficacy and safety of all medicines used in children, 219 
the prescribers should be informed about clinical trials involving off-label medication in which the patient 220 
could participate and inform the parents and – when applicable – also the children.  221 
  222 
Policy Statement: recommendations  223 
Off-label and unlicensed prescription practices occur. In order to facilitate the clinical practice of 224 
appropriate, rational and safe prescribing of off-label medicines to individual children, the EAP and 225 
ESDPPP strongly recommend that 226 
• All physicians prescribing medicines to neonates, children or adolescents have access to reliable and 227 
up-to-date information (where possible) on the medicine they prescribe. A European paediatric 228 
formulary with the best evidence on dosing and safety information could be a useful tool for improving 229 
the rational use of medicines in children and adolescents [15]. The BNF-c and the Dutch Formulary 230 
could serve as templates [16]. 231 
• Paediatric clinical pharmacologists/paediatricians/paediatric pharmacists should be actively 232 
involved/consulted in decision-making processes by hospital, Pharmacotherapeutics Committees and 233 
national health care authorities. 234 
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• Enhanced safety monitoring and reporting by parents and caregivers should be promoted when off-235 
label medicines are prescribed.  236 
• Parents and patients but also the public should be educated about off-label and unlicensed use of 237 
medicines. 238 
• Where off-label use of a medicine is common and evidence-based, it should be the shared 239 
responsibility of marketing authorization holder and the relevant regulatory authorities to take 240 
appropriate measures to address legal uncertainty and safety concerns. 241 
• Health authorities and health insurances should support, and thus reimburse, therapeutic practices 242 
that are evidence-based or advocated by a respectable and responsible body of professional opinion, 243 
regardless of labelling status. 244 
• Legislation should be adopted that aims to effectively stimulate research into off-label medicines, 245 
including non-publication of clinical trial data [29]) and facilitate the registration of off-label uses with a 246 
positive benefit-harm balance.  247 
 248 
Conclusion 249 
HCPs often have no other option than to prescribe medicines to children outside the approved conditions 250 
for age, therapeutic indication, dose recommendation, formulation and/or route of administration. This 251 
EAP/ESDPPP policy statement is intended to offer practical guidance to these HCPs on when and how to 252 
prescribe off-label medicines to children. Several conditions should be considered when prescribing off-253 
label medicines. This list of conditions may serve as a checklist for defensible, good practice.  254 
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Table 1:  National temporary recommendations for off-label use of medicinesa 
Country When off-label prescribing? How? 
Belgium The evaluation of the individual 
practitioner’s choice implies an 
evaluation of possible alternatives, 
including alternative treatments, 
alternative medicinal treatments, and 
alternatives to a treatment, but in 
essence there is ‘therapeutic freedom’.  
After informed consent of the parents and 
patient, and after clinical examination.    
France  
No. 2011-2012 act (RTU) 
If prescriber deems it necessary for 
patient, given scientific knowledge and 
absence of available alternative 
treatment 
Or  
If medicine is part of 
“Recommendations for use (RTU)” 
scheme. An RTU for off-label use can be 
issued by the French Agency if certain 
criteria are met. 
Prescriber must justify choice; 
Informed consent is required; 
If medication is part of RTU: prescriber should 
mention this on prescription, so that 
pharmacists can control prescription in this 
context. The marketing authorisation holder 
should set up patient follow up. 
RTU medicines are reimbursed by the 
national health insurance. 
Italy 
National Law n. 94/98 (Di 
Bella Law), 648/96 
national Law 
If indication relates to therapeutic area 
with unmet medical need and  
Companies do not want to perform 
clinical trials for given indication. 
Off-label use requires support of phase II 
completed study; 
Informed consent is required; 
Reimbursed if application of law 648/96 
Spain 
National Royal Decree No. 
1015/2009 
Off-label use has to be exceptional and 
only limited to those situations in which 
no approved alternative exists, with 
respect to any restriction of the 
conditions for prescribing and 
dispensing established in the 
authorization and the therapeutic 
protocol of the centre. 
Prescriber has to justify need in the clinical 
history; 
Informed consent is required; 
Prescriber must notify adverse events; 
Prescriber must comply with established 
recommendations and therapeutic protocols. 
Switzerland 
Federal law on medicinal 
products and medical 
devices, Art 9, Art 26 
If it is proven that there is no authorized 
or available alternative medicine that is 
applicable and equivalent. 
 
Hungary 
Art 25 of Act XCV (2005), 
subsection 6 
(1) If treatment with licensed 
medicine is not possible or 
unsuccessful 
Or 
(2) Access to licensed medicine is 
inhibited to an extent that would 
likely delay treatment. 
Prescriber must ensure that 
(1)  
Based on experimental evidence, medicine 
offers potential of successful treatment or 
improve/stabilize patient condition; 
Medicine is licensed for distribution in 
Hungary or another country; 
Prescriber is specialist in specific therapeutic 
Table
area; 
Prescriber’s request for use of this medicine 
in specific patient has been granted by 
government body for pharmaceuticals.’ 
(2)  
Risk/benefit balance of off-label medicine is 
better than that of the licensed medicine; 
Based on experimental evidence, medicine 
offers potential of successful treatment or 
improve/stabilize patient condition; 
The SmPC of licensed medicine does not 
contain contra-indication regarding requested 
unlicensed indication. 
 
Table 2:  National measures to regulate reimbursement of off-label medicinesa 
Country When off-label prescribing? How? 
Belgium There is a Special Solidarity Fund for 
individual patients, but the fund has 
limited resources. This is because the 
Belgian reimbursement regulation is 
based on a positive list of reimbursed 
products. Consequently, off label can 
potentially qualify for reimbursement, 
nor necessary linked to an indication or 
age category.   
 
Hungary  Case-by-case evaluation: decision to 
reimburse is taken based upon circumstances 
(including existing alternatives and reasons 
why these are not sufficient) and costs. 
Germany 
Section 92 para (1) Nr. 6 
SGB V 
 The German Agency decides if off-label 
medicines are reimbursed based on a 
scientific evaluation by its off-label expert 
commissions.  
Costs should be refunded also if there are 
only weak references for efficacy, on 
condition that the patient suffers from a life-






 Ministerial decree is required in special cases 
and according to international bibliographic 
references. 
Off-label indications could be reimbursed if 
included in therapeutic protocols approved by 
the Central Committee of Health Council. 
 
Table 3:  National guidance to professionals on off-label medicine use in childrena  
Country When off-label prescribing? How? 
Belgium  When a suitable tested and approved 
alternative is available, prescribing physicians’ 
liability may be at (increased) risk if safety 
issues arise. If an adverse event arises 
through the use of that drug, the treating 
physician would have the burden of proof to 
demonstrate that its use was performed as 
standard of care. Key characteristics: usual or 
common practice, scientific basis and 
informed consent. 
Lithuania 
Law of Pharmacy No. X-
709 (2006)  
Law of Patients’ rights, 
safety and compensation 
of harm No. I-1562 (1996) 
 Off-label use of licensed medicines is possible 
based on the decision of a council or group of 
clinical pharmacologists if applicable. In the 
outpatient setting it is possible to prescribe 
off-label and extemporaneous medicines 
based on experience and personal decision. 
Sweden 
SFS 2010:659 and SFS 
2014:821 
 If there is sufficient scientific evidence and 
clinical experience to prescribe medicine 
Informed consent is required. 
United Kingdom 
Good practice in 
prescribing and managing 
medicines and devices, 
2013 
 Prescriber must be convinced there is 
sufficient evidence or experience of using 
medicine to demonstrate its safety and 
efficacy; NICE publishes evidence summaries 
for off-label and unlicensed medicines. 
Prescriber has responsibility for prescribing 
the medicine; 
Prescriber is responsible for overseeing 
patient’s care, monitoring and follow-up (or 
should ensure this is done by another suitable 
physician); 
Prescriber must have clear, accurate and 
legible record of prescribed medicines and 
reasons for prescribing medicine off-label; 
Informed consent is required. 
Paediatric: 
Royal College of Paediatrics and Child Health 
(Rev 2, 2013) [24]: 
Where available, an appropriate licensed 
preparation should be prescribed and 
supplied in preference to an unlicensed 
preparation. 
In general, it is not necessary to take 
additional steps, beyond those taken when 
prescribing licensed medicines, to obtain 
consent of parents, caregivers and child 
patients to prescribe or administer unlicensed 
medicines or licensed medicines for 
unlicensed applications (off-label)b. 
The Netherlands 
Art 68 of Medicines Act 
If relevant professional body has 
developed protocols or professional 
standards with regard to the specific 
off-label use. 
If protocols or standards are under 
development, prescriber and 
pharmacist are required to consult each 
other. 
Paediatric: 
Dutch Paediatric Society (Rev 4, 2018) [26]: 
The Dutch Paediatric Society has accepted the 
National Paediatric Formulary as expert 
guideline.  
Off-label use is considered appropriate if 
there is a medical need (no registered 
medicine available or registered medicine is 
suboptimal for individual patient].  
There should be a positive balance between 
expected efficacy and risks based on available 
literature and assessed within 
multidisciplinary setting. 
Informed consent is required unless off-label 
use is documented in National Paediatric 
Formulary or in professional guideline. 
The prescribing physician should inform 
parents/caregivers/child about the benefits 
and risks of off-label or unlicensed use of 
medicines. 
Off-label treatment with medicines should be 
regularly and rigorously monitored and 
adverse events should be reported nationally. 
 
Tables 1-3: aBased on information provided by EAP members and data included in [4,27,30]; bUsed definitions for off-label and unlicensed use 
may vary across countries and publications2. For example, in the UK, off-label use of drugs is referred to as “unlicensed use of licensed drugs”. 
No data: countries not participating in EU study: e.g., Luxemburg, Norway, Switzerland, Iceland, Latvia, Poland, Romania, Croatia, Albania, 
Macedonia, Serbia, Bosnia and Herzegovina. 
 
